We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$717M
AUM Growth
+$143M
Cap. Flow
+$179M
Cap. Flow %
24.96%
Top 10 Hldgs %
42.64%
Holding
176
New
63
Increased
14
Reduced
29
Closed
31

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$15.9M
2
RCUS icon
Arcus Biosciences
RCUS
+$9.44M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.44M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.12M
5
BPMC
Blueprint Medicines
BPMC
+$8.44M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20.7M
2
SLNO
Soleno Therapeutics
SLNO
+$10.7M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.35M
4
NUVL
Nuvalent
NUVL
+$8.24M
5
AMGN icon
Amgen
AMGN
+$8.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RZLT icon
51
Rezolute
RZLT
$454M
$4.3M 0.6%
887,230
-16,514
-2% -$75.8K
AMGN icon
52
Amgen
AMGN
$208B
$4.29M 0.6%
13,300
-25,000
-65% -$8.18M
XENE icon
53
Xenon Pharmaceuticals
XENE
$6.06B
$4.22M 0.59%
107,187
– –
EOLS icon
54
Evolus
EOLS
$385M
$4.18M 0.58%
+258,279
New +$3.61M
BDTX icon
55
PUT
Black Diamond Therapeutics
BDTX
$96.8M
$4.13M 0.58%
+950,000
New +$5.17M
ABEO icon
56
Abeona Therapeutics
ABEO
$366M
$3.69M 0.51%
583,593
-185,000
-24% -$966K
RCKT icon
57
Rocket Pharmaceuticals
RCKT
$340M
$3.64M 0.51%
197,096
– –
PYXS icon
58
Pyxis Oncology
PYXS
$168M
$3.51M 0.49%
957,408
-705,000
-42% -$2.47M
SLN
59
Silence Therapeutics
SLN
$495M
$3.37M 0.47%
587,343
+80,678
+16% +$1.5M
SLRN
60
DELISTED
ACELYRIN
SLRN
$3.34M 0.47%
677,074
-798,000
-54% -$4.12M
HELP
61
Cybin Inc
HELP
$485M
$3.26M 0.46%
367,195
-2
-0% -$20
BDTX icon
62
CALL
Black Diamond Therapeutics
BDTX
$96.8M
$3.04M 0.42%
+700,000
New +$3.81M
CRVO icon
63
CervoMed
CRVO
$23.9M
$2.95M 0.41%
202,345
-35,000
-15% -$542K
TRML
64
DELISTED
Tourmaline Bio
TRML
$2.79M 0.39%
108,483
– –
CYTK icon
65
CALL
Cytokinetics
CYTK
$10.5B
$2.76M 0.39%
+52,300
New +$2.92M
SANA icon
66
CALL
Sana Biotechnology
SANA
$871M
$2.7M 0.38%
650,000
+646,000
+16,150% +$3.39M
SANA icon
67
PUT
Sana Biotechnology
SANA
$871M
$2.7M 0.38%
650,000
+646,000
+16,150% +$3.39M
TERN
68
DELISTED
Terns Pharmaceuticals
TERN
$2.57M 0.36%
308,497
-150,000
-33% -$1.23M
ALNY icon
69
Alnylam Pharmaceuticals
ALNY
$27.5B
$2.4M 0.34%
+8,741
New +$2.28M
LXEO icon
70
Lexeo Therapeutics
LXEO
$324M
$2.33M 0.32%
+257,216
New +$3.07M
CRBP icon
71
CALL
Corbus Pharmaceuticals
CRBP
$166M
$2.22M 0.31%
+107,800
New +$5.52M
MLYS icon
72
Mineralys Therapeutics
MLYS
$2.25B
$2.18M 0.3%
+180,000
New +$2.18M
SLDB icon
73
CALL
Solid Biosciences
SLDB
$794M
$2.09M 0.29%
+300,000
New +$2.43M
OKUR
74
OnKure Therapeutics
OKUR
$154M
$1.74M 0.24%
+102,567
New +$1.52M
RCUS icon
75
CALL
Arcus Biosciences
RCUS
$3.55B
$1.74M 0.24%
+113,700
New +$1.79M
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ikarian Capital held 176 positions worth $717M, up 25% from $574M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $179M of net new capital in Q3 2024, opening 63 new positions and adding to 14 existing holdings. Its largest new stake was BeOne Medicines Ltd: 88,167 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20.7M trimmed.

  • Ikarian Capital's largest Q3 2024 buy was BeOne Medicines Ltd: 88,167 shares worth $1.64M.
  • Ikarian Capital added most to Arcus Biosciences in Q3 2024, an estimated $9.44M increase.
  • Ikarian Capital's biggest Q3 2024 reduction was Sarepta Therapeutics, cutting an estimated $20.7M.
  • Ikarian Capital fully exited Immunovant in Q3 2024, selling an estimated $8.17M.
  • Ikarian Capital's ten largest holdings make up 43% of its $717M portfolio in Q3 2024.
  • Ikarian Capital opened 63 new positions and closed 31 in Q3 2024.
  • Ikarian Capital's portfolio value rose 25% quarter-over-quarter to $717M.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.